Skip to content
TESCT — Trans European Stem Cell Therapy Society
European committee room

Policy

Evidence into
health policy.

An ageing, co-morbid population needs particular attention on prevention. The society argues for policy that is evidence-based, value-based and patient-centred.

The challenge

Europe's health systems are not failing for lack of science.

Healthcare systems and citizens across Europe and worldwide are facing unprecedented challenges driven by an ageing population and an increased prevalence of chronic diseases. Mental disorders have become Europe's largest health challenge in the 21st century. The study by the European College of Neuropsychopharmacology (ECNP, 2011) also highlights that the majority of mental disorders remain untreated. Taken together with the large and increasing number of ‘disorders of the brain', the true size and burden is even significantly higher.

There is a need to develop coordinated and strategic planning for health research and increase collaborative efforts across Europe to tackle the major health challenges facing Europe. Through better use of health data and measuring health outcomes, health policies can become more evidence-based, value-based and patient-centred.

01

Health economy

There is a need to develop coordinated and strategic planning for health research and increase collaborative efforts across Europe to tackle the major health challenges facing Europe.

02

Disease prevention

With better prevention, hundreds of thousands of lives can be saved every year in the EU and EU citizens can live their lives in good health. Prevention, including primary prevention, screening and vaccination, as well as investing in the prevention of chronic disease progression, will have the advantage of reducing both health- and socio-economic costs.

The TESCT Society should help to implement, together with patient organisations and other healthcare stakeholders, standards for measuring patient-relevant health outcomes across diseases and conditions, as well as to measure healthy lifespan on a population level.

03

Social and ethical responsibility

Dr. Mary Baker: “The sad thing is that pharma companies are not involved in the major health systems; they're peripheral. They should not be seen as a cost, they should be seen as a trusted partner.”

  • Current member of the Strategic Advisory Board of the Human Brain Project
  • Immediate Past President of the European Brain Council
  • Past President of the European Federation of Neurological Associations
  • Associate Membership of the Health Services Research Unit, University of Oxford
  • Visiting Fellow within the London School of Economics (LSE) Health Centre
  • Consultant to the World Health Organization (WHO)

04

Patient database and artificial intelligence

Through better use of health data and measuring health outcomes, health policies can become more evidence-based, value-based and patient-centred.

Patient safety and regulation

Off-label use, which is the practice of using a medicine outside its authorised indication, is often necessary in areas of unmet medical needs but poses challenges in terms of therapeutic innovation, patient safety and professional liability. There is currently no harmonised approach to off-label use across the EU (EBC, Annual Report 2017, Brussels).

06

Trans-European healthcare policy

Public health policymakers, healthcare managers, providers and patients across Europe should be able to make decisions based on the best available evidence. Comparative outcomes data will help determine which medical practices, care pathways and providers have demonstrated the best results.

07

Medical ethics and the right to science

The TESCT Society is convinced that science, and the scientific method, are a clear example of fact-based collaborations to address global challenges.

Right to science

Science and the scientific method are a fact-based collaboration to address global challenges.

World Congress